Summary & Overview
HCPCS J3394: Injection, lovotibeglogene autotemcel, per treatment
HCPCS Level II code J3394 denotes the administration of lovotibeglogene autotemcel, a gene-modified cellular therapy delivered as a per-treatment injectable product. This code captures a high-cost, one-time or limited-course biologic therapy that has implications for specialty pharmacy distribution, hospital outpatient billing, and high-acuity clinical management. Nationally, accurate coding of such therapies is critical for appropriate claims adjudication, care coordination, and tracking utilization of advanced therapeutics.
Key payers in the national landscape include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare and Medicare. The publication outlines what organizations and payers typically consider when processing claims for a cell- or gene-based injectable, and highlights the administrative touchpoints that affect coverage and payment workflows.
Readers will find benchmarks and operational context for billing and claim submission, summaries of the clinical service setting and typical sites of care, and a policy-focused overview of payer engagement for specialty biologics. Where specific data elements were not provided in the input, the text notes that the information is not available. The piece is intended for billing managers, revenue cycle professionals, clinicians involved in therapy administration, and policy analysts tracking specialty biologics reimbursement.
Billing Code Overview
HCPCS Level II code J3394 represents the medication Injection, lovotibeglogene autotemcel, per treatment. This entry codes for administration of a gene-modified cellular therapy product provided as a single treatment dose.
-
Service type: Injectable biologic/cell therapy
-
Typical site of service: Hospital outpatient department or specialized infusion/cellular therapy center
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 6-year-old child with a confirmed diagnosis of a monogenic inherited retinal disorder or other eligible genetic ophthalmic condition is scheduled to receive J3394 (injection, lovotibeglogene autotemcel, per treatment) as a one-time gene therapy treatment. The patient presents to a hospital outpatient infusion suite or ambulatory surgical center for evaluation on the day of service. Pre-procedure workflow includes verification of patient identity and consent, confirmation of prior authorization, review of genetic testing and ophthalmology records, baseline ophthalmic exam and visual function documentation, and anesthesia assessment. The treatment is administered under sterile conditions by a specialty-trained ophthalmic surgeon or gene therapy team using intraocular injection technique with appropriate peri-procedural medications. Post-administration monitoring occurs in a post-anesthesia care unit or observation area to assess for immediate adverse events, with discharge instructions and scheduled ophthalmology follow-up visits for efficacy and safety assessments.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier (default) | Use when no special circumstance applies to the service. |